The intestinal immune system has the challenging task of tolerating foreign nutrients and the commensal microbiome, while excluding or eliminating ingested pathogens. Failure of this balance leads to conditions such as inflammatory bowel diseases, food allergies and invasive gastrointestinal infections
, but, to our knowledge, the underlying cellular components and functional consequences of gut segment-specific drainage have not been systematically addressed. We sought to understand how compartmentalized lymphatic drainage of the intestinal milieu contributes to distinct immune responses towards luminal antigens. We first imaged the gut lymphatic system using 3D imaging of solvent-cleared tissue stained with an antibody against the lymphatic endothelial cell (LEC) surface marker LYVE-1. En bloc imaging exposed the lymphatic route of the intestine to gLNs via afferent lymphatic vessels in the mesentery . The size and shape of individual gLNs differs considerably regardless of the presence or absence of microbiota (Extended Data Fig. 1d , e). Dye injected into individual gLNs did not spread to other gLNs, suggesting that the lymph remains compartmentalized until it reaches the thoracic duct (Extended Data Fig. 1f-i) . Injection of dye into the intestinal muscularis confirmed that the gLNs drain different gut segments [9] [10] [11] [12] despite the network-like lymphatic structure in the gut wall (Extended Data Fig. 1j -q, Supplementary Videos 5-7). The progressive shortening of the lymphatic lacteals in the villi along the small intestine is modulated by the microbiome, as germ-free mice showed lengthened duodenal and shortened ileal lacteals (Extended Data Fig. 2a ). To investigate whether the combination of compartmentalized absorption and drainage results in differential nutrient exposure in the gLNs, we tracked the uptake of radiolabelled retinol after feeding; retinol is a lipid-soluble proxy and an immunomodulatory nutrient, and its uptake depends largely on packing into chylomicrons and lymphatic absorption by the upper small intestine (Extended Data Fig. 2b ). Most retinol was absorbed in the duodenum with a gradient along the intestine, and this was mirrored in the gLNs (Fig. 1d , e, Extended Data Fig. 2b-g ), illustrating that the gLNs are exposed to region-specific lymph composition.
We investigated how compartmentalized drainage affects gLNs on a cellular level. Stromal cells of pooled gLNs were shown to be tolerance-promoting compared to non-intestinal lymph nodes 14, 15 , so we analysed the transcriptomes of two major stromal cell populations, lymphatic endothelial cells (LECs) and fibroblastic reticular cells (FRCs), isolated from duodenal, ileal and caecal-colonic gLNs (D-, I-and C-gLNs, respectively; Extended Data Fig. 3a) . Principal component analysis (PCA) indicated that LECs and FRCs showed differential gene expression according to the gut segment the gLNs drained (Fig. 1f) . LECs from D-gLNs showed a distinct metabolic signature indicative of elevated cholesterol and lipoprotein handling as well as fatty acid utilization, probably driven by the lipid-rich lymph of the proximal small intestine (Fig. 1g, . FRC gene expression profiles were affected in a more pronounced manner by location, most evidently in immune cell migration and activation pathways, which were upregulated in the C-gLN (Fig. 1h, Extended Data Fig. 3e, . Differences within the small intestine were less extreme, although FRCs from I-gLNs also showed a gene signature associated with leucocyte stimulation (Extended Data Fig. 3f, g ).
Because stromal cells may influence the function of antigen-presenting cells (APCs) in gLNs 14 , we tested whether gut-segment-specific lymphatic drainage influenced the gene expression profiles of migratory dendritic cells. The two populations of MHCII hi migratory dendritic cells (CD103
+

CD11b
-and CD103 + CD11b + dendritic cells; Extended Data Fig. 3h ) are highly represented in gLNs and have been implicated in tolerogenic and pro-inflammatory responses, respectively 16, 17 . PCA revealed that dendritic cells segregated between the small and large intestine, and less so between D-gLNs and I-gLNs (Fig. 2a) . Both subsets of dendritic cells showed immunological and metabolic differences according to gLN location (Fig. 2b, c, ). Duodenal-gLN dendritic cells showed a less pro-inflammatory signature than their colonic counterparts: D-gLN CD103
+
CD11b
+ dendritic cells expressed lower levels of inflammatory cytokine receptors and pathways such as interferon or interleukin-1β Fig. 2b 
-dendritic cells were specifically enriched for Ccl22, which encodes a chemokine associated with migration of T reg cells,
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and the T reg -promoting factor Aldh1a2, which encodes a rate-limiting enzyme for retinoic acid 11 production from retinol (Fig. 2c, Extended Data Fig. 3j, . Differences in retinoic acid production capacity between small-and large-intestine gLNs were preserved in germ-free mice (Extended Data Fig. 3o-q) , but the ratio of CD103
+
CD11b
-to CD103
+
CD11b
+ dendritic cells was inverted in all gLNs analysed when compared to SPF mice (Extended Data Fig. 3r ). These data suggest that D-gLNs are more tolerogenic environments than I-gLNs and C-gLNs, at least in part owing to favourable dendritic cell and stromal cell signatures, and that this tolerogenicity is boosted by the microbiota. Overall, each gLN appears to be poised to mount an appropriate immune response corresponding to the environment of the intestinal region that it drains.
We next investigated whether CD4 + T cell fates correlated with migratory dendritic cell profiles or the presence of microbiota. Although germ-free mice harboured fewer T reg (FOXP3 + ) cells than control mice in the small and large intestines 18 , we observed no difference between germ-free and specific pathogen-free (SPF) mice in the numbers of T reg cells in gLNs (Extended Data Fig. 4a-c) . T H 17 (RORγT + ) effector cells and their corresponding suppressive RORγT + pT reg cells can be induced by the microbiota [1] [2] [3] , and germ-free mice displayed a severe reduction in RORγT + pT reg cells in all tested gLNs, although there was no significant decrease in T H 17 cells (Fig. 2d, Extended Data Fig. 4d, e) . We then tracked T cell responses to segmented filamentous bacteria (SFB)-pathobionts that elicit a strong T H 17 response and preferentially colonize the ileum and colon 19, 20 and found that monocolonization of germ-free mice with SFB led to enrichment of RORγT + CD4 + T cells only in the I-and C-gLNs (Fig. 2e) . To test whether initial CD4 + T cell polarization occurs in a compartmentalized manner, we adoptively transferred naive ovalbumin (OVA)-specific CD4
+ cells (CD45.1 OT-II cells) into SPF mice and analysed the activation of the transferred cells upon OVA gavage
17
. OT-II cells proliferated and were activated in all gLNs, with the exception of the iliac and caudal gLNs (Extended Data Fig. 4f-i) .
We then assessed CD4 + T cell fate and its dependence on the microbiota. Amongst the retained OT-II cells (Extended Data Fig. 5a ), we observed a gradient of pT reg cell induction that declined in a proximal-to-distal manner (Fig. 2f) . In germ-free mice, pT reg cell induction was decreased in all gLNs when compared to SPF mice (Fig. 2f , Extended Data Fig. 5b ), despite having similar antigen access, induced proliferation and increased CD25 expression by transferred OT-II cells in upper small intestine gLNs (Extended Data Fig. 5c-g ), suggesting that the less favourable dendritic cell composition in germ-free gLNs contributed to this effect. Limited antigen availability was also unlikely to explain the gradient of OT-II pT reg cells in the small intestine and C-gLNs of SPF mice, as proliferation and CD25
+ cell frequencies did not differ between these gLNs (Extended Data Fig. 5f, g ). Furthermore, intravenous administration of OVA also resulted in a decreasing proximal-to-distal gradient of FOXP3 induction, but similar OT-II cell recovery and proliferation among gLNs (Fig. 2g, . By contrast, OT-II RORγT + T H and OT-II RORγT + pT reg cells showed an ascending proximal-to-distal gradient that was independent of the microbiota (Fig. 2h, i) and correlated with an increase in IL12/23p40 + frequency among CD103 + CD11b -dendritic cells (Extended Data Fig. 5n ). These data indicate that under homeostatic conditions, the D-gLNs are the primary sites for induction of pT reg cells by dietary antigens. By contrast, distal gLNs favour differentiation of T H 17 and RORγT + pT reg cells, underscoring the immunological distinctness of the proximal and distal intestinal milieus.
We investigated the possible consequences of anatomical segregation of T cell fates along the intestine. First, we analysed T cell responses to an antigen delivered to distinct intestinal sites by surgical injection of OVA-containing solution into the duodenum or ileum. This approach did not elicit significant induction of RORγT -pT reg cells, possibly because of the pro-inflammatory surgical setting and lack of postprandial mechanisms. Ileal injection of OVA elicited more pronounced differentiation of RORγT + T H and RORγT + pT reg cells than duodenal injection of OVA in the respective draining gLNs; this response pattern was boosted by co-injection of cholera toxin (CT; Fig. 3a , Extended Data Fig. 6a-h ). This result confirms that I-and C-gLNs have a greater pro-inflammatory potential than D-gLNs. We next injected CT-OVA into the ileum or duodenum and compared these mice to shamoperated mice for susceptibility to OVA-expressing Salmonella enterica Typhimurium (Stm-OVA), which infects the ileum and caecum before systemic dissemination. Only mice previously injected with CT-OVA in the ileum displayed delayed weight loss compared to sham-operated 3 H]retinol in 100 µl olive oil with or without pre-treatment with 5 µl chylomicron formation inhibitor Pluronic L-81 (PL81) 3 h before gavage (n = 4 per group). f, RNA sequencing (RNA-seq) PCA of FRCs and LECs sorted from D-, I-and C-gLNs (for example, cLEC denotes LECs from C-gLNs) from SPF C57BL/6 mice (n = 3, pooled from two mice each). PC1 accounts for 65.1% and PC2 for 5.7% of the variance. g, h, Volcano plots depicting genes that are differentially expressed among LECs (g) and FRCs (h) from D-or C-gLNs (CL and DL, LECs from C-and D-gLNs, respectively; CF and DF, FRCs from C-and D-gLNs, respectively). Blue, metabolismrelated genes; red, immunity-related genes. C, colon; C1, caecal colonic; C2, ascending colonic; D, duodenum; D1, portal lymph nodes; D2, distal duodenum gLNs; Pan, pancreas; I, ileum; ing, inguinal lymph node; IL and CA, iliac and caudal (both rectal) gLNs; J, jejunum. *P < 0.05, **P < 0.01, ***P < 0.005 (ANOVA); mean ± s.e.m.
Letter reSeArCH mice (Fig. 3b, c, Extended Data Fig. 6i ), which correlated with reduced Salmonella invasion and an increased frequency of RORγT + pT reg and T H 17 cells in the lamina propria (Extended Data Fig. 6j-l) . We then tested whether infection with Citrobacter rodentium, which is anatomically restricted to the caecum and colon, perturbed proximal induction of pTreg cells. Induction of OVA-specific pT reg cells in D-gLNs by oral administration of OVA was unaffected by infection with OVAexpressing Citrobacter, which resulted in OVA-specific CD4 + T cell activation in the C-gLNs (Fig. 3d , e, Extended Data Fig. 6m-p) , or by infection with wild-type Citrobacter (Extended Data Fig. 6q-u) .
The gLNs are crucial for physiological responses to microbiota, pathogen-resistance mechanisms and oral tolerance 7, 21, 22 . We investigated whether the I-and C-gLNs are required for the generation of SFBspecific T H 17 cells. After transfer of naive SFB-specific CD4 + T cells (7B8tg cells) 2 into SPF mice colonized with SFB, we recovered substantial numbers of transferred cells only from the I-and C-gLNs, which upregulated RORγT expression (Fig. 3f , g, Extended Data Fig. 7a-e) . Surgical removal of I-and C-gLNs shifted the SFB-specific T H 17 cell response to the gLNs that drain gut segments with lower colonization (Fig. 3f, g, Extended Data Fig. 7a-g ), and this change correlated with ectopic expansion of 7B8tg cells in the intestine, but only if some SFB was present in the lumen owing to recent colonization (Extended Data Fig. 7a -c, h-s). It is unlikely that surgery caused lymph rerouting to surrounding gLNs, because dye did not spread to adjacent lymph nodes, or expansion of SFB into surrounding gut segments, as evidenced by SFB-specific 16S qPCR (Extended Data Fig. 8a-c) . Hence, these data suggest that individual gLNs also modulate T cell responses in the intestinal tissue in a region-specific manner. In the presence of pathogens or pathobionts, this regionalization may help to contain tissue damage. Together, these results illustrate the beneficial effects of discrete gLN Hash denotes fewer than 200 cells. *P < 0.05, **P < 0.01, ***P < 0.005; NS, not significant (one-tailed t-test or ANOVA). naive CD45.1 + OT-II cells into SPF CD45.2 mice infected or not with OVA-expressing Citrobacter (Citro-OVA) 9 days earlier, and after gavage of OVA 48 h and 24 h before analysis (n = 5, representative of two independent experiments). f, Experimental design for g. g, Frequency of Vβ14
+ cells in indicated gLNs from mice after sham operation (n = 12) or surgical removal of the I-and C1-gLNs (ΔicLN, n = 14), 64 h (day 3, f) after adoptive transfer of 4 × 10 5 naive SFB-specific CD45.1 + 7B8tg cells into SPF CD45.2 mice; pooled data from three independent experiments with n = 4-5 per group each. *P < 0.05, **P < 0.01, ***P < 0.005 (one-tailed t-test or ANOVA).
drainage, which may avoid immunological conflict between responses induced at different gut sites and help to preserve these responses in the tissue.
Viral and bacterial gastrointestinal infections can perturb the generation of pT reg cells that recognize dietary antigens and subsequently impair oral tolerance 6, 23 . We investigated whether the proximal gLNs alone are necessary or sufficient for oral tolerance, a pT reg cell-dependent process 4 , by surgical removal of the D-gLNs or the I-and C-gLNs followed by the induction of asthma suppression mediated by an oral antigen 17 . Oral tolerance was intact following the removal of proximal or distal lymph nodes (Extended Data Fig. 8d-i ), probably because pT reg cells generated in remnant gLNs are sufficient to maintain tolerance 17 . To induce immunological conflict only in the proximal intestine-draining gLNs, we chose the helminth Strongyloides venezuelensis, which displays distinct duodenal tropism 24 . Upon infection with S. venezuelensis, only the D-gLNs were swollen, underwent significant restructuring and displayed increased immune cell counts compared to gLNs of non-infected mice, and this was consistent with compartmentalized duodenal worm load ( 
CD11b
-and CD8α + dendritic cell subsets; D-gLNs also showed a type 2 immunity signature comprising eosinophils, GATA3
+ T H 2 cells and GATA3 + T reg cells even after the infection was cleared . Upon infection with S. venezuelensis, transferred OT-II cells showed a significant reduction in OVA gavage-induced upregulation of FOXP3 (P < 0.01 for D1 and D2) and CD25 (P < 0.001 (D1), P < 0.05 (D2)) specifically in the D-gLNs (P < 0.01 for D1 and D2) compared to non-infected mice, despite a similar frequency of CD45.1 cells being recovered (Fig. 4i , Extended Data Fig. 10a-e) . Finally, we investigated whether transient infection during initial antigen exposure affected tolerance to dietary antigens 17 ( Fig. 4j ). Mice infected with S. venezuelensis showed partial impairment of suppression of eosinophilia and dendritic cell infiltration into bronchial-alveolar lavage fluid (BALF) and lungs, and increased OVAspecific IgG1, compared to non-infected mice ( Fig. 4k -m, Extended Data Fig. 10f, g ). Together, these data show that duodenal infection can perturb local responses and alter systemic tolerance to gut antigens.
Our data uncover a mechanism by which the intestinal immune system simultaneously handles regulatory versus pro-inflammatory responses: by anatomical segregation of these reactions into functionally distinct gLNs. They also show that effector (T H cells) and corresponding regulatory mechanisms (lineage-defined T reg cells) (n = 8, pool of two independent experiments) infected with S. venezuelensis larvae or not infected 8 days before analysis, and gavaged with OVA 48 h and 24 h before analysis. j, Scheme of oral tolerance experimental set-up in S. venezuelensis-infected mice. k-m, Total eosinophils in BALF (k), frequency of eosinophils among CD45 + cells in lung tissue (l) and OVA-specific IgG1 levels in serum (m) from mice infected with S. venezuelensis or not infected during antigen feeding (+OVA groups) or no feeding (-OVA groups), 21 days after first immunization with OVA-alum (j) (n = 13 for +OVA groups, n = 10 for -OVA groups, pool of two independent experiments). *P < 0.05, **P < 0.01, ***P < 0.005; NS, not significant (one-tailed t-test or ANOVA).
Letter reSeArCH may co-operate at every site to dampen excessive, gut segment-specific inflammation. It remains to be determined whether the presence of specific dendritic cell subpopulations with varying tolerogenic or inflammatory roles in specific gLNs mediate distinct responses to dietary, microbiota or pathogen-derived antigens 3, 16 . The efficient drainage of dietary antigens into tolerance-promoting lymph nodes associated with the proximal intestine suggest that these lymph nodes help to prevent food allergies, and that duodenal infection and dysbiosis can alter the allergic outcome. However, the dietary duodenal route could be exploited therapeutically for inducing tolerance to otherwise inaccessible pro-inflammatory antigen sources, such as dysbiotic bacteria in patients with inflammatory bowel diseases, while selective targeting of distal gLNs might lead to successful intestinal vaccination.
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Mice. C57BL/6J CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ) mice were from Jackson laboratories, CD45.2 (C57BL/6) mice were purchased from Jackson Laboratories or Taconic Farms, and CD45.1 OT-II TCR-transgenic mice were originally purchased from Taconic Farms and maintained in our facilities. B6.Cg-Tg(ItgaxVenus)1Mnz/J mice were provided by M. Nussenzweig (The Rockefeller University). C57BL/6-Tg (Tcra,Tcrb)2Litt/J (7B8tg) mice were either purchased from Jackson Laboratories or provided by D. Littman (NYU). Mice were used at 7-12 weeks of age, and male mice were used throughout the study. A minimum of biological triplicates was used throughout the study. For in vivo studies, the maximum number of mice available per treatment group was used to counteract biological variation: for all adoptive transfer experiments up to five mice per group, for oral tolerance experiments up to eight mice per group, for infection and surgery experiments up to eight mice per group. For surgeries (lymph node removal, intestinal antigen injection and OVA+ cholera toxin surgery), surgical group sizes were larger than sham group sizes (two additional mice) to allow for the possibility that a mouse might have to be euthanized during post-operative care owing to the higher invasiveness of the procedure. All surviving animals were included in the study. For all studies B6 mice were purchased in batches of 10-20 mice and randomly distributed to cages. Infection/colonization studies: cages of five mice were randomly infected or colonized with SFB or not. Because of the high chance of contamination it was not possible to house infected/colonized and non-infected mice together. CT-OVA injection: mice were housed in cages of 4-5 mice and within a cage randomly subjected to sham, duodenal or ileal OVA or OVA-CT injection, ensuring that mixed groups were present in each cage (2 vs 2, 2 vs 3, or 2 vs 2 vs 1). Surgery: mice were housed as five mice per cage, and each cage housed 2 vs 3 or 3 vs 2 sham operation versus lymph node removal surgery mice, to avoid any potential microbial drift or behavioural changes due to the different treatments affecting the study outcome. Blinding was not possible in this study as the experimenters treating the mice were the same as those that analysed the data. The treatment groups had to be clearly identified throughout the study to prevent cross contamination (gnotobiotic/infection experiments), to be able to draw conclusions (CT-OVA injection in duodenum versus ileum) or were obvious by their anatomy (lymph nodes were removed). Statistics were applied in an unbiased manner. Mice were maintained at the Rockefeller University animal facilities under specific pathogen-free conditions or germ-free conditions. Germ-free C57BL/6 mice were generously provided by S. Mazmanian (Caltech) and imported into germ-free flexible film isolators (Class Biologically Clean Ltd). Mice monocolonized with SFB were kept in flexible film isolators and originally colonized by gavage with faecal extracts from SFB monocolonized mice kept at NYU (Littman laboratory). SFB colonization was verified by real-time PCR using SFB-specific 16S primers; germ-free faeces served as a negative control and Taconic Farms B6 faeces as a positive control. The mice were bred in our germ-free facility for maintenance of the strain and kept on sterilized Autoclavable Mouse Breeder Diet (5021, LabDiet, USA), which was also used for control (ex-germ-free) SPF mouse breeding and maintenance. Rats. Female Wistar rats (6-10 weeks old) were purchased from Charles River. I were from Perkin-Elmer. Cholera toxin was from List Biological Laboratories (cat. no. 100B). Antibodies, staining and flow cytometry. Fluorescent-dye-conjugated antibodies were purchased from BD (USA) (anti-CD25, 563061; anti-CD45.1, 563982; anti-CD45.2, 560693; anti-CD31, 557355; anti-CD103, 557495; anti-LY6C, 560595; anti-NK1.1, 562921; anti-SiglecF, 552126; anti-RORγT, 562894; anti-IL17A, 56022 and 559502; anti-Vβ5.1, 553190; anti-Vβ14, 553258), eBioscience (USA) antiCD11c, ; anti-I-A/I-E (MHCII), and streptavidin, , or Biolegend (USA) (anti-CD3ε, 100320; anti-CD8α, 100744; anti-CD11b, 101236; anti-CD64, 139306; anti-TCRβ, 109220; anti-TER119, 116206) . Additional antibodies were purchased from BioXCell and labelled in-house (anti-CD4, BE0003-1; anti-CD8α, BE0004-1; anti-CD11b, BE007; anti-CD19, BE0150; anti-TCRβ, BE00102). Biotinylated antibodies were purchased from BD Pharmigen (anti-B220, 553086; anti-CD8α, 553029; anti-CD11b, 553309; anti-CD11c, 553800; anti-CD25, 553070; anti-NK1.1, 553163; and anti-TER-119, 553672) or as follows: anti-IgG1, Bethyl, A90-105B; anti-IgG2c, Bethyl, A90-136B; anti-IgE, eBioscience, 13-5992-82; and anti-neuropilin, R&D Systems, BAF566. Unconjugated antibodies used were anti-LYVE1, R and D Systems AF2125; anti-GFP, Aves Labs, GFP-1020; anti-OVA IgG1, Biolegend, 520501; anti-IgE, Invitrogen, RMGE00; and IgE isotype control, eBioscience 554118. Horseradish peroxidase-conjugated streptavidin was purchased from Jackson ImmunoResearch Laboratories, Inc. Aqua LIVE/DEAD Fixable Aqua Dead Cell Stain Kit, L-34965, Cell Trace CFSE and Violet Cell Proliferation kits (C34554 and C34557) were purchased from Life Technologies. For cytokine analysis in T cells, cells were incubated for 3.5 h in RPMI medium with 10% fetal bovine serum (FBS), brefeldin A (0.5 µg ml -1 , Sigma B7651), ionomycin (0.5 µg ml -1 , Sigma I0634), and phorbol 12-myristate 13-acetate (100 ng ml -1 , Sigma P8139); for cytokine analysis in dendritic cells, cells were incubated for 6 h in RPMI with 10% FBS and GolgiPlug (1 to 1,000, BD Biosciences 555029). Cell populations were stained with Aqua in phosphate-buffered saline (PBS), followed by incubation with Fc block and antibodies against the indicated cell surface markers in fluorescence-activated cell sorting (FACS) buffer (PBS, 1% BSA, 10 mM EDTA, 0.02% sodium azide). The cells were analysed live, or fixed in 1% PFA/PBS. For intracellular staining, cells were first stained for surface epitopes and then fixed, permeabilized and stained according to the manufacturer's protocol (eBioscience 00-5123-43). Flow cytometry was performed on an LSRII (BD Biosciences) and analysed using FlowJo software (Tree Star). Cell division index was calculated using the FlowJo formula (http://www.flowjo.com/v765/en/proliferation.html), in which the index represents the fraction of total cell divisions over the calculated total starting cells. Tissue clearing, light sheet microscopy and image reconstruction. For tissue clearing and staining, the iDISCO protocol was followed as detailed on the continuously updated website http://idisco.info, with the following specifics: tissues were stained in primary and secondary antibodies for 4 days each, and were embedded in 1% agarose-TAE before final dehydration. Blocks were imaged using a LaVision Ultramicroscope II and software. Images were reconstructed using Imaris 8 software. Fast green tracing. Mice were anaesthetized with isoflurane and their peritoneal cavity exposed. For mapping intestine to lymph node drainage, 3-5 µl of 10% Fast Green in PBS was injected into the muscularis of the intestine using a nanoinjection device (Nanoject III, Drummond). Spreading of green colour through the lymphatics was followed until it accumulated in the draining lymph node and until it faded again (sham-operated mice) and reached the duodenal lumen via the bile duct (no longer than 15 min). The same timing was applied in mice in which ileal and caecal mesenteric lymph nodes (mLNs) had been removed, even though the dye never accumulated in a lymph node. To trace lymphatic mLN efflux, 1-3 µl of 10% Fast Green was injected into the centre of the mLN, and efflux monitored for 15 min or until the dye was detected in the thoracic duct. [ 3 H]retinol biodistribution. Mice were fasted for 3 h before gavage with 150 µl PBS with or without 5 µl chylomicron formation-inhibiting Pluronic L-81, followed by 1 µCi [ 3 H]retinol in 100 µl olive oil 30 min later, and sampled at indicated time points. Serum was sampled from the submandibular vein (systemic) or from the portal vein. Lymph was collected from the thoracic duct under isoflurane anaesthesia using a custom-made glass needle (micropipette puller, Sutter Instruments). Dissected organs were weighed before lysis by mechanical disruption in 0.5 ml hypertonic lysis buffer with 1% Triton-X 100; the lysate was mixed with 7 ml Ultima Gold scintillation cocktail (Perkin Elmer) and accumulation of radioactivity was measured on a scintillation counter. Input radioactivity was estimated by counting 10% of the gavaged material. Segmentation of gut-draining lymph nodes. The mouse gLNs consist of one hepatic-coeliac lymph node co-draining the duodenum, pancreatic-duodenal lymph nodes draining the duodenum and separately the ascending and transverse colon, the main mLN chain draining the distal duodenum, jejunum, ileum, caecum and proximal ascending colon, and the caudal and iliac lymph nodes draining the descending-distal colon. Mesenteric lymph nodes draining intestinal segments were identified anatomically by following the lymphatic vessels connecting the colon, ileum and jejunum to their lymph nodes. Duodenal lymph nodes were revealed by gavaging with 100 µl of olive oil (Sigma) and determining the most stomach-proximal lymph nodes surrounded by chyle, indicative of duodenal drainage, 1 h after gavage. Isolation of lymphocytes and APCs from lymph nodes. Lymph nodes were dissected into cold Hanks' balanced salt solution (HBSS) supplemented with Mg 2+ and Ca
2+
, finely chopped and incubated in 400 U/ml collagenase D (Roche) in HBSS for 25 min at 37 °C, 5% CO 2 . Collagenase was quenched on ice by addition of a final 10% FCS. Single cell suspensions were extracted from connective tissue by taking up and resuspending the digests five times. Erythrocytes were lysed by incubation in erythrocyte lysis buffer (Sigma) for 7 min at room temperature. Isolation of stromal cells from gLNs. Gut lymph nodes were dissected into 500 µl cold RPMI, supplemented with 2% FCS and HEPES (dissection medium). Tissues Letter reSeArCH were disrupted using 25 G needles, and Liberase TL (Roche) was added to a final concentration of 0.25 mg/ml with collagenase D (Roche) to a final concentration of 400 U/ml. Tissues were incubated at 37 °C on an orbital shaker at 80 r.p.m. for 10 min, and disrupted at room temperature by gently pipetting the digest up and down 50 times, followed by an additional 20 times. The reaction was stopped by placing the digest on ice and adding 14 ml of ice-cold dissection medium. Cells were spun down at 700g for 5 min at 4 °C, resuspended in erythrocyte lysis buffer (Sigma), topped up with medium again, spun and then subjected to staining. Isolation of lymphocytes and APCs from small and large intestines. Intestines were separated from mesentery, and Peyer's patches (small intestine) and faeces were removed. For segmentation of the small intestine, the upper 25% of the small intestine was taken as duodenum, the next 50% as jejunum and the last 25% as ileum. This division allowed quick processing of multiple specimens, though it can lead to some contamination of the ileum and duodenum with jejunum. The caecum was included in the preparation of the large intestine. Intestines were cut longitudinally and washed twice in PBS. Tissue was cut into 1-cm pieces, mucus was removed by incubating the tissue for 10 min in PBS and 1 µM DTT, and the epithelium was removed by two incubations in 25 ml of HBSS, 2% FCS and 30 mM EDTA for 10 min at 37 °C at 230 r.p.m. with vigorous shaking after each incubation. Tissues were washed in PBS over a sieve, then finely chopped and digested in 6 ml of RPMI per gut segment (Gibco), 2% FCS, 200 µg/ml DNaseI (Roche) and 2 mg/ml collagenase 8 (Gibco) for 45 min at 37 °C, 5% CO 2 . Digests were taken up and resuspended 10 times and passed through a sieve, and the collagenase was quenched by addition of 15 ml cold RPMI, 2% FCS. Cell pellets were resuspended in 40% Percoll (BD Pharmigen) complemented with RPMI, 2% FCS, passed through a 100-µm mesh and separated by centrifugation in a discontinuous Percoll gradient (80%/40%) at 1000g for 25 min at room temperature. APCs and lymphocytes were isolated from the interphase, washed, and stained for FACS analysis or subjected to re-stimulation. Cell isolation for RNA-seq. C57BL/6 male mice (10-14 weeks old) served as gLN donors, and biological triplicates or quadruplicates were collected. Cells were sorted using a FACS Aria cell sorter flow cytometer (Becton Dickinson). Dendritic cells from mLNs were pre-enriched using a Pan Dendritic Cell Isolation Kit Miltenyi Biotec) 
CD11c
-cells, and the subpopulations were sorted further as podoplanin +
CD31
-(FRCs) and podoplanin + CD31 + (LECs). Three hundred cells were sorted directly into 25 µl TCL buffer (Qiagen, 1031576) supplemented with 1% β-mercaptoethanol at single cell precision. Samples were kept at room temperature for 5 min, spun down and kept at -80 °C until further processing. RNA-seq library preparation and sequencing. RNA was isolated using RNAClean XP beads (Agentcourt, A63987) on a magnetic stand (DynaMag, Invitrogen 12331D). Reverse transcription primers were: P1-RNA-TSO: Biot-rArArUrGr ArUrArCrGrGrCrGrArCrCrArCrCrGrArUrNrNrNrNrNrNrGrGrG; P1-T31: Biot-AATGATACGGCGACCACCGATCG31T; P1-PCR: Biot-GAATGATACGG CGACCACCGAT. RNA was eluted for 1 min at room temperature in cDNA synthesis mix 1 (0. 5 µl P1-T31 (20 µM), 0.3 µl RNasin plus (Promega, N2615), 1.5 µl 10 mM dNTP, 3.5 µl 10 mM Tris pH 7.5, 0.5% IGEPAL CA-630 (Sigma) and 1.7 µl RNase free ddH 2 O) and the beads pipetted up and down ten times. The eluted sample was then incubated for 3 min at 72 °C, followed by 1 min on ice, then 7.5 µl of mix 2 was added (3 µl 5× FS Buffer SS, 0.375 µl 100 mM DTT, 0.375 µl RNasin plus, 0.5 µl P1-RNA-TSO (40 µM), 0.75 µl Maxima RT Minus H (Thermo Scientific, EP0751), 1.8 µl 5M Betaine (Sigma, B0300), 0.9 µl 50 mM MgCl2 and 0.175 µl RNase free ddH 2 O. Reverse transcription occurred during a thermal cycle of one cycle (90 min at 42 °C), 10 cycles (2 min at 50 °C, 2 min at 42 °C) and one cycle (15 min at 70 °C), and the product was kept at 4 °C. The cDNA was then amplified using 15 µl of the reverse transcription product, 20 µl 2× KAPA HiFi HS Ready Mix (Kapabiosystems, KK2601), 1.5 µl P1-PCR (10 µM), and 3.5 µl RNase-free ddH 2 O. Amplification occurred during the following cycles: one cycle of 3 min at 98 °C, 20 cycles of (15 s at 98 °C, 20 s at 67 °C, 6 min at 72 °C), and one cycle of 5 min at 72 °C, and the product was kept at 4 °C. PCR product (20 µl) was cleaned up using 16 µl RNAClean XP beads. The cDNA was eluted in 20 µl RNase-free ddH 2 O and kept at -20 °C. Isolated amplicons were confirmed to be 1,500-2,000 bp long by a High Sensitivity DNA Assay (Bioanalyzer). Concentration of all sample was measured on a Qubit fluorometer (Thermo Fisher), all samples were adjusted to 0.1 ng/µl with ddH 2 O, and 2.5 µl cDNA was subjected to Nextera XT DNA Library preparation (Illumina) using a Nextera XT Index Kit (Illumina, FC-131-1002) according to the manufacturer's protocol, except that all volumes were used at 0.5× the indicated volumes. Sample quality was again verified by Bioanalyzer, and sample concentrations were measured on the Qubit fluorometer and adjusted to a concentration of 4.54 ng/µl. All samples were pooled at equal contributions and run in multiple lanes. Sequencing was performed using 76-base single-end reading on a NextSeq instrument (Illumina). RNA-seq data analysis. Gene expression was quantified using the raw fastq files and the mouse reference transcriptome M18 (Gencode, GRCm38.p6) as input for Kallisto (v.0.43.0) . The resultant normalized transcript frequencies were provided to the R package Sleuth for differential analysis (v.0.30.0). Analyses were conducted at the gene level, and the likelihood ratio test was applied to capture gene expression differences among all groups. When testing between group pairs, the Wald test was used to determine differentially expressed genes. Genes with log 2 fold changes greater than 1 or less than -1 and a false discovery rate (FDR) of 0.05 were considered significant for downstream studies. Gene set enrichment analysis (GSEA) was performed by ranking genes based on log 2 fold changes of paired comparisons and subsequently run as a GSEA preranked analysis (GSEA v3.0) with the c5.all. v6.1.symbols.gmt (Gene Ontology) gene set database. All pathways with an FDR of 0.25 or less were considered significantly different. RALDH activity assay. RALDH activity was determined using the Aldefluor kit (STEMCELL Technologies) according to the manufacturer's protocol. Cells were analysed by flow cytometry 30 min after the addition of substrate.
125
I-OVA labelling and biodistribution. Iodination of OVA was performed as described previously 18 . Mice were fasted for 3 h before gavage with 4 × 10 6 CPM 125 I-OVA and 50 mg cold OVA (grade III) in 200 µl PBS, and samples were taken at 1 h and 5 h post gavage. The wet weight of tissues was measured before measuring radioactivity on a gamma counter (Packard Cobra). Input radioactivity was estimated by counting 10% of the gavaged material. Adoptive T cell transfer. Naive CD4 T cells from spleen and lymph nodes were isolated by negative selection using biotinylated antibodies against CD8α, CD25, CD11c, CD11b, TER-119, NK1.1, and B220 and anti-biotin MACS beads (Miltenyi Biotec). The purity of transgenic CD4 + T cells was verified by flow cytometry (CD45.1
CD25
-for OT-II cells, CD45.1
-for 7B8tg cells, typically >90%). T cells were labelled using the Cell Trace Violet or CFSE Cell Proliferation Kit (Life Technologies). For OT-II cells, 1 × 10 6 cells were transferred by retro-orbital injection under isoflurane gas anaesthesia. For 7B8tg cells, 4 × 10 5 cells were transferred for analysis of gLNs 60 h post-transfer and 5,000 cells for analysis 7 days or more after transfer in the gut and gLNs. Oral antigen administration. OVA (grade III, Sigma, A5378) was administered at 50 mg in 200 µl PBS by gavage using metal gavage needles. Two doses were given with a 24-h interval, the first dose given 16-24 h after adoptive OT-II cell transfer. Intravenous antigen administration. Endotoxin-low OVA (Worthington) was administered by retro-orbital injection at either 1 mg or 0.1 mg in 100 µl PBS 16 h after adoptive OT-II cell transfer. The high dose corresponds to the maximum of 125 I-OVA recovered in blood upon OVA gavage (4% of 50 mg gavage per ml plasma, see Extended Data Fig. 5e , equivalent to 2% in blood, estimating the blood volume of a 20 g mouse is around 1 ml equating to 1 mg); the ten times lower dose is equivalent to doses used previously 11 . Intestinal CT-OVA injection. Naive OT-II cells were adoptively transferred into 7-week-old C57B6 mice 16-24 h before surgery (1 × 10 6 cells for T cell fate analysis in gLNs, 1 × 10 5 for subsequent Stm-OVA infection). Mice were anaesthetized subcutaneously with 100 mg/kg ketamine (controlled substance provided by the Rockefeller University animal facility), 10 mg/kg xylazine (Akorn), and in the presence of 5 mg/kg analgesic meloxicam (Putney) in 0.5 ml saline. The abdominal area was then shaved, and sterilized by three cycles of wiping with iodine solution and 70% ethanol after 20 µl of 0.25% bupivacaine (Hospira, Inc.) was injected intradermally at the prospective site of incision. The mouse was placed on a heat mat and covered by sterile surgical plastic with an opening above the abdomen. All work from here was performed aseptically. Skin was incised in the middle of the abdomen and the peritoneum was cut open. Filter-sterilized PBS solution (100 µl) containing 50 mg OVA and 5 µg cholera toxin or not was injected into the duodenum (5 mm after the pylorus) or the ileum (5 mm before the most distal Peyer's patch) using a 28.5 G needle pointing towards the distal intestine. The peritoneal muscles were aligned and sutured using absorbable suture (PDS*II, Ethicon), the skin closed with autoclips (Ken Scientific Corp.), and the wound covered with Triple Antibiotic Ointment (Honeywell Safety Products, USA). Mice were allowed to fully awaken in a cage placed on a heat mat. For sham surgery, mice were opened and sutured again. Mice that had undergone different surgeries were pooled in cages. On the day after surgery, mice were monitored for agility and passing stool. Mice were treated with 0.3 mg/kg of buprinex (controlled substance) and 5 mg/kg meloxicam 24 h after the first meloxicam treatment and every 24 h for another 3 days. Stm-OVA infection. Seven days after CT-OVA injection, mice were gavaged with 20 mg streptomycin in 200 µl PBS. On the same day, Stm-OVA was grown overnight to stationary growth phase in LB broth at 300 r.p.m. at 37 °C. On the next day, a 100 µl aliquot of Stm-OVA was sub-cultured in 3 ml LB broth. After 3.5 h, 50 µl subculture was diluted in 50 ml PBS, giving rise to a density of 10 5 CFU per 100 µl, and mice were immediately gavaged with 100 µl of this solution. The infection was timed such that 24 h had elapsed since streptomycin administration and the mice had been fasted for 4 h before infection. Initial body weight was taken just before gavage. Mice were weighed every 24 h after infection. In the survival study, mice were killed when their weight reached 80% or less of their starting weight. For analysis of Stm-OVA dissemination, mice were killed 48 h after infection, and CFU in organs was determined by serial dilutions on Salmonella Shigella agar plates. C. rodentium and Citro-OVA infection. Mice were infected with 1-2 × 10 9 CFU of C. rodentium or Citro-OVA. For Citro-OVA infection, mice were kept on 100 mg/l kanamycin in drinking water to ensure the OVA-expressing plasmid was not lost. Non-infected control mice were also kept on kanamycin. Infection was monitored by plating faeces onto MacConkey agar plates. Nine days after infection, 1 × 10 6 naive OT-II cells were adoptively transferred and mice subjected to OVA gavage as described above. SFB colonization. SFB was obtained from frozen stocks of caecal contents (kept at -80 °C for less than 6 months) of mice monocolonized with SFB, which were diluted in PBS (2 ml/caecum) and passed through a 70-µm mesh. Mice were colonized by two gavages of 0.4 ml of caecal content preparation, 24 h apart. Colonization was verified by real-time PCR of faecal DNA (Quick-DNA Fecal/Soil microbe miniprep kit, Zymo research, Cat. No. D6010). PCR was performed in the presence of Power SYBR Green PCR master mix (Applied Biosystems, 4367659) on a Quant Studio 3 PCR machine (Applied Biosystems), using SFB-specific 16S primers (fwd: GACGCTGAGGCATGAGAGCAT; rev: GACGGCACGGATTGTTATTCA) The SFB Ct value was normalized by the Ct obtained in the PCR using universal bacterial 16S primers (fwd: ACTCCTACGGGAGGCAGCAGT; rev: ATTACCGCGGCTGCTGGC). Lymph node surgery. Mice were prepared and sutured and monitored postoperatively as for CT-OVA injection. To expose the ileal and caecal lymph nodes, the caecum was gently pulled out using cotton tipped applicators soaked in saline. To expose the upper duodenal lymph nodes, the duodenum was shifted to the left just under the pylorus; the same loop was shifted to the right to expose the distal duodenal gLNs. Lymph nodes were removed by holding onto the lymph node with tweezers and gently pulling it while slowly and closely cutting around the node with microsurgical scissors, such that no bleeding occurred. For sham operation, the caecum was pulled out and the lymph nodes exposed for 2 min. The caecum was then placed back into its original position and the peritoneal cavity filled with 0.5 ml pre-warmed saline. Mice were allowed to recover from surgery for twelve days before colonization with SFB (Jax mice), nineteen days before adoptive transfer of 7B8tg cells, and two weeks before OVA gavage (oral tolerance).
S. venezuelensis passage and infection. S. venezuelensis was maintained in
Wistar rats by subcutaneous infection with 30,000 larvae. On day 6-8 after infection, the caecum (containing eggs) was removed and spread on Whatman paper, which was placed into a beaker with water at 28 °C. The hatching larvae were collected over 4 days and the cycle re-initiated. Mice were infected subcutaneously with 700 larvae per mouse. Adult worm load was assessed in total epithelial scrapes from the gut. Alum immunization and airway challenge. Seven days after oral administration of OVA, 4 µg of endotoxin-free OVA antigen adsorbed to 40 µl Imject Alum Adjuvant (Fisher Scientific) was injected intraperitoneally in a final volume of 400 µl made up with PBS. Immunization was repeated after 7 days. To induce airway inflammation, mice were anaesthetized and intranasally administered 10 µg of sterile OVA grade VI in 50 µl PBS (25 µl per nostril) on days 14, 17 and 21 after the first intraperitoneal immunization. Total IgE was measured to confirm previous infection with S. venezuelensis (250-350 ng/ml in plasma compared to 5-10 ng/ ml in plasma of uninfected mice) 18 . Bronchoalveolar lavage (BAL), lung histology and infiltrate analysis by flow cytometry. Mice were anaesthetized by intraperitoneal injection of 0.35 ml 2.5% avertin (Sigma), the trachea was cannulated and lungs were lavaged once with 0.5 ml and then with 1.0 ml PBS. Total BAL cells were counted after erythrocyte lysis and stained for FACS analysis. Lungs were perfused via the right ventricle with 10 ml saline to wash out residual blood. One lobe was digested in 400 U/ml collagenase D/HBSS and processed for FACS analysis. 
Data availability
Source data for all figures are provided with the paper. For RNA-seq experiments the raw and processed data generated here can be obtained at the Gene Expression Omnibus database under the accession code: GSE121811.
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Extended Data Fig. 3 | Extended analysis of gLN stromal and dendritic  cell differences according to gut segment drained. a, Flow + (q) dendritic cells from gLNs from germ-free and SPF C57BL/6 mice (n = 3) assessed by flow cytometry 30 min after the addition of substrate. r, Ratio of CD103 + CD11b + to CD103 + CD11b -dendritic cells in gLNs from SPF and germ-free mice (n = 4, representative of two independent experiments ) . *P < 0.05, **P < 0 . 01, ***P < 0.005; ns, not significant (one-tailed t-test or ANOVA). Fig. 4 + CD11b -dendritic cells in indicated gLNs of germ-free and SPF C57BL/6 mice (n = 4 per group). #, fewer than 200 cells were recovered. *P < 0.05, **P < 0.01, ***P < 0.005; ns, not significant (one-tailed t-test or ANOVA). Fig. 6 | Extended analysis of OT-II .2 C57BL/6 host mice infected or not with Citrobacter 9 days earlier, and after gavage with OVA 48 h and 24 h before analysis (n = 5). ns, not significant in ANOVA or one-tailed t-test comparing gLNs of infected versus non-infected mice. *P < 0.05, **P < 0.01, ***P < 0.005 (ANOVA); # P < 0.05 (t-test). Fig. 3g (a) + 7B8tg cells (n = 4). Hash, fewer than 200 cells were recovered. *P < 0.05, **P < 0.01, ***P < 0.005 (one-tailed t-test or ANOVA); ns, not significant. Fig. 8 | Effect of selective gLN removal on lymph flow, SFB colonization and oral tolerance. a, Fast Green tracing of ileal lymphatic drainage to the gLNs of SPF C57BL/6 mice, 5 min after injection of 3 µl Fast Green in sham-operated (left, biological duplicates; Extended Data Fig. 2g) or ΔicLN (middle and right, biological triplicates) mice 3 weeks after surgery. Red arrows, sites of injection. b, c, Relative quantification of SFB-specific 16S in luminal contents of indicated gut segments from recently SFB-colonized SPF C57BL/6 Jax mice (b, n = 13 per group from four independent experiments) or parentally colonized Taconic mice (c, n = 7 per group from four independent experiments) after sham or ΔicLN surgery. d-i, Total eosinophils (d) and dendritic cells (e) in BALF and frequency of eosinophils (f) and dendritic cells (g) among CD45
Extended Data
Letter reSeArCH
Extended Data
+ cells in lungs, and total IgE (h) and anti-OVA IgG1 (i) in serum from SPF C57BL/6 mice subjected to oral tolerance as in Fig. 4k but without S. venezuelensis infection, 14 days after sham surgery (n = 7), I-and C-gLN removal (ΔicLN, n = 5) or D-gLN removal (ΔdLN, n = 6). Data are representative of two independent experiments. ns, not significant (ANOVA). + cells in lung tissue (g) from non-infected SPF C57BL/6 mice or mice infected with S. venezuelensis during antigen feeding (+OVA groups) or no feeding (-OVA groups), 21 days after first immunization with OVA-alum (n = 13 for +OVA groups, n = 10 for -OVA groups). Data are pooled from two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.005; ns, not significant (one-tailed t-test or ANOVA).
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